Research programme: IKur antagonists - Bristol-Myers Squibb

Drug Profile

Research programme: IKur antagonists - Bristol-Myers Squibb

Alternative Names: IKur antagonists

Latest Information Update: 09 Sep 2014

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Small molecules
  • Mechanism of Action Kv1.5 potassium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Atrial fibrillation

Most Recent Events

  • 10 Jul 2014 No development reported - Preclinical for Atrial fibrillation in USA (unspecified route) prior to July 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top